May. 17 at 3:45 AM
$KZIA Celcuity has delivered, via its positive phase 3 results. The company has justified this positive description of their drug. But Celcuity at nearly 50 times the size of Kazia, is cause for frustration - primarily through simple lack of market knowledge of paxalisib. ASCO news, this week is assured and cause for pAX hope. " Gedatolisib is an investigational pan-class I isoform PI3K and mTOR inhibitor with low nanomolar potency for the p110α, p110β, p110γ, and p110δ PI3K isoforms, as well as mTORC1 and mTORC2, that induces comprehensive blockade of the PAM pathway. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone. We believe this will enable gedatolisib to treat a broader patient population than these single-target inhibitors."
